格隆汇11月14日丨ST香雪(300147.SZ)在投资者互动平台表示，公司产品香雪抗病毒口服液具有清热祛 湿,凉血解毒功效，临床上广泛用于治疗感冒、流感、上呼吸道感染、腮腺炎、病毒性结膜炎、手足口 病等疾患。在抗击非典、甲型H1N1流感、禽流感、防控期间发挥了重要作用。 ...

格隆汇11月14日丨ST香雪(300147.SZ)在投资者互动平台表示，公司产品香雪抗病毒口服液具有清热祛 湿,凉血解毒功效，临床上广泛用于治疗感冒、流感、上呼吸道感染、腮腺炎、病毒性结膜炎、手足口 病等疾患。在抗击非典、甲型H1N1流感、禽流感、防控期间发挥了重要作用。 ...

Group 1 - The company emphasizes the clinical value and market potential of TAEST16001 and is actively advancing the preparatory phase for confirmatory clinical trials [1] - The company has previously disclosed progress in the new drug development stage and will continue to announce updates based on clinical situations in accordance with information disclosure rules [1] - Investors have raised concerns regarding the lack of transparency about the enrollment status of the confirmatory clinical trial, questioning why the company has not provided clear updates [3] Group 2 - The company has received recognition from the CDE for the confirmatory clinical trial plan for TAEST16001, but has not publicly disclosed whether the first patient has been enrolled [3] - Investors are demanding clarity on the enrollment status, indicating that this is a core asset and they have the right to be informed [3]

Core Viewpoint - The company is under scrutiny from investors regarding the status of its clinical trial for TAEST16001, with concerns about transparency in communication and adherence to disclosure rules [1] Group 1: Company Response - The company emphasizes the importance of TAEST16001's clinical value and market potential, stating that it is fully committed to advancing the preparatory phase of the confirmatory clinical trial [1] - The company has previously disclosed progress in the new drug development phase and will continue to provide updates based on clinical developments in accordance with information disclosure regulations [1]

Core Viewpoint - The company ST Xiangxue has received clinical trial approvals for its drug TAEST16001 targeting advanced esophageal cancer and advanced non-small cell lung cancer, but has not yet initiated Phase II clinical trials [2]. Group 1: Clinical Progress - TAEST16001 has obtained clinical trial approvals for both advanced esophageal cancer (2024LP02791) and advanced non-small cell lung cancer (2025LP00282) [2]. - As of now, the company has not started the clinical trials for these indications [2]. - Future research and development progress will be disclosed in accordance with information disclosure rules and actual circumstances [2].

Market Overview - The precision medicine sector experienced a decline of 1.77% on November 4, with TuoJing Life leading the drop [1][2] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] Stock Performance - Notable stock performances in the precision medicine sector included: - RenDu Bio (688193) closed at 52.90, up 1.05% with a trading volume of 7076.23 hands and a transaction value exceeding 36.99 million yuan [1] - TuoJing Life (300642) closed at 22.73, down 2.86% with a trading volume of 78,200 hands and a transaction value of 178 million yuan [2] - Other companies like DaAn Gene (002030) and Anke Bio (300009) showed minimal changes, with DaAn Gene remaining flat at 6.57 and Anke Bio down 0.55% to 10.84 [1][2] Capital Flow - The precision medicine sector saw a net outflow of 979 million yuan from institutional investors, while retail investors contributed a net inflow of 642 million yuan [2][3] - Specific stock capital flows indicated: - GuoMai Technology (002093) had a net inflow of 8.61 million yuan from institutional investors, while retail investors saw a net outflow of 15.98 million yuan [3] - TuoJing Life experienced minimal net inflow from institutional investors at 25,000 yuan, with retail investors also showing a slight outflow [3]

Group 1 - The company is currently in the pre-restructuring phase and has not yet entered restructuring [2] - According to the relevant regulations of the Shenzhen Stock Exchange's Growth Enterprise Market, the company has not triggered the delisting conditions mentioned by the investor [2]

Core Viewpoint - ST Xiangxue's subsidiary is advancing its drug development pipeline with two new drugs, TAEST16001 and TAEST1901, targeting various cancers, indicating a strong focus on oncology research and potential market opportunities [1] Drug Development Progress - TAEST16001 injection is currently undergoing confirmatory clinical trials for the treatment of advanced soft tissue sarcoma [1] - TAEST1901 injection is in Phase I clinical research for advanced liver cancer [1] - TAEST16001 has also received clinical approval for advanced esophageal cancer and advanced non-small cell lung cancer [1] - TAEST1901 has obtained clinical approval for advanced gastric cancer [1]

Core Viewpoint - ST Xiangxue (300147.SZ) is currently in the pre-restructuring phase and has not yet entered the restructuring process [1] Company Summary - The company is in the pre-restructuring stage, indicating that it is preparing for potential restructuring but has not formally initiated the process [1]

Core Viewpoint - ST Xiangxue announced the convening of its 31st meeting of the 9th board of directors on October 27, 2025, to review the full report for the third quarter of 2025 [1] Company Summary - For the first half of 2025, ST Xiangxue's revenue composition is as follows: Traditional Chinese medicine accounts for 64.87%, pharmaceutical manufacturing for 22.53%, other sectors for 20.22%, pharmaceutical distribution for 4.27%, and medical devices for 1.18% [1] - As of the report, ST Xiangxue has a market capitalization of 6.8 billion yuan [1]